AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37753446
Drug: OAC discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC discontinuation
Trial: 33355910
Drug: Tegoprazan 200
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 200 mg
Trial: 34436536
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg orally once daily) plus Letrozole (2.5 mg orally once daily)
Trial: 34436536
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg orally once daily)
Trial: 36271335
Drug: Oral esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral esomeprazole 20 mg, twice-daily for 36 weeks (Group D)
Trial: 36271335
Drug: Oral esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral esomeprazole 20 mg, once-daily for 36 weeks (Group S)
Trial: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 5 min before intercourse
Trial: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 15 min before intercourse
Trial: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 3 sprays administered 30 min before intercourse
Trial: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 1 spray administered 5 min before intercourse
Trial: 35314817
Drug: Fortacin™ (prilocaine/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortacin™ (prilocaine/lidocaine spray) - 5 sprays administered 5 min before intercourse
Trial: 33811367
Drug: Saroglitazar 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar 1 mg
Trial: 33160341
Drug: HIV prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV prevention methods (including condoms and daily oral PrEP)
Trial: 33160341
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable formulations (e.g., vaccines, passive antibodies, chemoprophylaxis)
Trial: 33389233
Drug: Spaced education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced education alerts through the Family Medicine Study Guide mobile app
Trial: 34126630
Drug: High-dose cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cranberry beverage (HCb; 480 mL)
Trial: 34126630
Drug: High-dose and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose and low-dose cranberry beverages (HCb and LCb)
Trial: 34126630
Drug: Low-dose cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose cranberry beverage (LCb; 240 mL cranberry beverage plus 240 mL placebo)
Trial: 34126630
Drug: Placebo (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (480 mL)
Trial: 32576084
Drug: Abemaciclib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib at full dose
Trial: 32576084
Drug: Ribociclib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib at full dose
Trial: 32576084
Drug: Ribociclib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib at reduced dose (400 mg)
Trial: 32576084
Drug: Ribociclib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib at reduced dose (200 mg)
Trial: 32576084
Drug: Palbociclib at
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib at full dose
Trial: 32576084
Drug: Abemaciclib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib at reduced dose
Trial: 33727798
Drug: Benfotiamine (150–1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (150–1200 mg single ascending doses)
Trial: 33727798
Drug: Benfotiamine (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (150, 300, or 600 mg multiple ascending doses)
Trial: 36300646
Drug: Inarigivir 25
RxNorm normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir 25 mg
Trial: 36300646
Drug: Inarigivir 50
RxNorm normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir 50 mg
Trial: 36300646
Drug: Inarigivir 100
RxNorm normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir 100 mg
Trial: 36300646
Drug: Inarigivir 200
RxNorm normalized name: Inarigivir
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir 200 mg
Trial: 36300646
Drug: Inarigivir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir (all doses)
Trial: 36300646
Drug: Inarigivir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir (all doses) during tenofovir treatment
Trial: 36300646
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during tenofovir treatment
Trial: 36039002
Drug: Antidepressant use
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant use in Black or African descent residents
Trial: 36039002
Drug: Antidepressant use
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant use in White residents
Trial: 35081076
Drug: Hydrocortisone therapy
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone therapy in immune-adaptive prevalent (IA-P) patients
Trial: 35081076
Drug: Hydrocortisone therapy
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone therapy in immune-innate prevalent (IN-P) patients
Trial: 33675704
Drug: Microfragmented adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfragmented adipose tissue injection using Lipogems technology
Trial: 33675704
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with hyaluronic acid injection
Trial: 34447851
Drug: Neostigmine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (2.5 mg/100 ml normal saline)
Trial: 34447851
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg/100 ml normal saline)
Trial: 33904601
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing propolis extract, nanovitamin C and nanovitamin E, used as toothpaste three times/day for 1 month.
Trial: 34561695
Drug: Cobicistat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobicistat (150 mg q24h orally)
Trial: 34561695
Drug: Cobicistat with
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cobicistat with GHB (25 mg/kg)
Trial: 34561695
Drug: GHB alone
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB alone (25 mg/kg)
Trial: 35604203
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine
Trial: 36351185
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (control group).
Trial: 33228787
Drug: On-site testing
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site testing and antiviral treatment for influenza (baloxavir or oseltamivir depending on age and comorbidities)
Trial: 33314786
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing blended with brief Cognitive Behavioural Therapy (MI‐CBT)
Trial: 35086501
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of foregoing substance abuse treatments as a predictor for aftercare matching.
Trial: 32302790
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy (FT)
Trial: 32302790
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy (FT) with neoadjuvant agents
Trial: 32302790
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy (FT) alone
Trial: 616121608
Drug: Panretinal photocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panretinal photocoagulation (PRP) with intravitreal Ranibizumab (RBZ) injections (study group, SG)
Trial: 36372680
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (1 ml)
Trial: 36372680
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (1 ml)
Trial: 32615663
Drug: Saffron pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron pill
Trial: 33955685
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to primary systemic therapy
Trial: 33955685
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to first‐line therapy
Trial: 33955685
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more lines of systemic therapy
Trial: 36243386
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 μg BID
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 100 μg QD
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 200 μg QD
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 400 μg QD
Trial: 36243386
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) therapeutic range (800 μg/day)
Trial: 36243386
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) therapeutic range (1000 μg/day)
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) >3-fold above therapeutic dose range (644 μg/day)
Trial: 33928435
Drug: Compression-only therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression-only therapy (CT) in a supine position
Trial: 33753319
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided Erector Spinae Plane Block (ESPB) with 30 mL of 0.375% ropivacaine on each side
Trial: 33753319
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (postoperative muscular infiltration with 30 mL of 0.75% ropivacaine)
Trial: 85119806
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Schistosoma haematobium infection
Trial: 32912103
Drug: Analgesic medication
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic medication on most days
Trial: 32912103
Drug: Interference with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interference with daily activities
Trial: 32467522
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac (60 mg/2 ml)
Trial: 35427803
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab 0.5‐mg injections
Trial: 35427803
Drug: PDS 100‐mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS 100‐mg/ml vs Monthly ranibizumab
Trial: 33764642
Drug: PO‐001 (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO‐001 (sustained-release cysteamine bitartrate) 600 mg
Trial: 33764642
Drug: Cystagon® (immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystagon® (immediate-release cysteamine)
Trial: 33764642
Drug: Procysbi® (delayed-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procysbi® (delayed-release cysteamine)
Trial: 32102263
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BJ) 70 mL
Trial: 32957340
Drug: Intravenous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous low-dose ketamine
Trial: 38358703
Drug: Present-centered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-centered therapy (PCT)
Trial: 32307932
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of low-level laser therapy (LLLT) 1 hour before the insertion of elastomeric separators
Trial: 32307932
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of low-level laser therapy (LLLT) 1 hour before and immediately after the insertion of elastomeric separators
Trial: 35678643
Drug: Community children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community children (CC)
Trial: 34119067
Drug: Pembrolizumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab alone or with chemotherapy
Trial: 32424361
Drug: Therapeutic administration
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic administration of a single amino acid to experimentally infected mice
Trial: 33993746
Drug: Daily rating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rating strategy
Trial: 34611052
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg/kg of body mass
Trial: 32819465
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy with riociguat (MED group)
Trial: 36336248
Drug: Centrally-administered system-wide
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrally-administered system-wide implementation + local-tailored implementation
Trial: 36336248
Drug: Centrally-administered system-wide
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrally-administered system-wide implementation only
Trial: 34837418
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet of mosapride 5 mg, pancreatin 170 mg, and simethicone 125 mg
Trial: 34837418
Drug: Single-component mosapride
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-component mosapride tablets (reference product)
Trial: 33110044
Drug: Fennel seed
RxNorm normalized name: FENNEL SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fennel seed powder (2 gr, four capsules daily for 8 weeks)
Trial: 33110044
Drug: Starch-containing capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch-containing capsules (2 gr, four capsules daily for 8 weeks)
Trial: 36434348
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants (type 1)
Trial: 36434348
Drug: Delayed implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implants (type 4)
Trial: 32700956
Drug: Light Therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light Therapy (LT)
Trial: 32484623
Drug: 1% colloidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% colloidal oat eczema cream
Trial: 34510141
Drug: Synthetic CBD
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic CBD 20 to 30 mg daily for 12 weeks
Trial: 33939897
Drug: l-carnitine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine (50 mg/kg/day, twice a day for three months)
Trial: 32111307
Drug: Montmorillonite (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorillonite (0.5 g/kg)
Trial: 32111307
Drug: Bacillus subtilis
RxNorm normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus subtilis (5 × 10^8 cfu/kg) and Montmorillonite (0.5 g/kg) combination
Trial: 33201054
Drug: Epithelial debridement,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epithelial debridement, aggressive lubrication, bandage contact lenses, reduction in chemotherapeutic dose to maintenance levels
Trial: 35769693
Drug: Sublingual sufentanil
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sufentanil tablet (SST)
Trial: 35769693
Drug: Standard-of-care (patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (patient-controlled epidural analgesia [PCEA] or PCA morphine)
Trial: 33345583
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders for Homeless Women (UPHW)
Trial: 33512807
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk oligosaccharides (HMOs) - 5g daily dose of 2'‐fucosyllactose and lacto‐N‐neotetraose in a 4:1 mix
Trial: 34773474
Drug: Erlotinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib + momelotinib (200 mg QD)
Trial: 34773474
Drug: Erlotinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib + momelotinib (100 mg BID)
Trial: 34773474
Drug: Erlotinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib + momelotinib (various doses)
Trial: 34088249
Drug: Mental health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental health interventions focusing on depressive symptoms and behavior change skills (e.g., self-efficacy)
Trial: 35672861
Drug: Preoperative inspiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative inspiratory muscle training using Power®Breathe KHP2, 30 breaths twice a day for at least 2 weeks before surgery (can be extended up to 6 weeks).
Trial: 35993772
Drug: In-hospital liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital liquid nitrogen therapy
Trial: 35235197
Drug: Biofeedback +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback + fiber laxative (psyllium)
Trial: 35235197
Drug: Biofeedback +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback + osmotic laxative (polyethylene glycol; PEG)
Trial: 32179564
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy (iCBT) for Depression, available only in Finnish.
Trial: 36205538
Drug: COBRA-light (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-light (prednisolone 30 mg/day tapered to 7.5 mg/day, MTX increasing to 25 mg/week)
Trial: 36205538
Drug: Intensification (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification (prednisolone 60 mg/day tapered to 7.5 mg/day, addition of SSZ (2 g/day) and HCQ (400 mg/day))
Trial: 36205538
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy increasing to 25 mg/week
Trial: 36205538
Drug: Intensification (prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification (prednisolone 30 mg/day tapered to 7.5 mg/day)
Trial: 35959775
Drug: Placebo (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose injection)
Trial: 36170281
Drug: Minimal-flow: 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-flow: 0.25 l.min-1 via endotracheal tube
Trial: 36170281
Drug: Low-flow: 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow: 2 l.min-1 + continuous jaw thrust
Trial: 36170281
Drug: Medium-flow: 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-flow: 10 l.min-1 + continuous jaw thrust
Trial: 36170281
Drug: High-flow: 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow: 70 l.min-1 + continuous jaw thrust
Trial: 36170281
Drug: Control: 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: 70 l.min-1 + continuous video-laryngoscopy